GlassScriptPhysician profile
Faisal S Hamada
NPI 1851387799
$1,080.42
in general payments reported to CMS, 2019-2025
11 companies · $90.23 in 2025
The $90.23 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $134 · 2021: $181 · 2022: $143 · 2023: $167 · 2025: $90.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $501.54 | 2019-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $268.27 | 2019-2025 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.96 | 2019-2020 | |
| Pfizer INC. | $48.78 | 2021-2023 | |
| Inogen, INC. | $47.58 | 2025 | |
| Allergan, INC. | $31.16 | 2019 | |
| Genentech USA, INC. | $21.59 | 2019 | |
| Amgen INC. | $21.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.09 | 2022 | |
| Inspire Medical Systems, INC. | $16.07 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Hamada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.